Sugi Predict

Sugi Predict / Compounds / SCHEMBL20745285

SCHEMBL20745285

SCHEMBL20745285

CN(C)c1cccc(CO)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 2/20 0.40
▸ CCR1 P32246 1/20 0.40
▸ NCF1 P14598 1/20 0.39
▸ ACACB O00763 1/20 0.35
▸ HTR1A P08908 4/20 0.35
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGA5 P08648 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549750 1.00 PDE10A (0.40) PDE10ACCR1NCF1ACACBHTR1A
SCHEMBL15341668 0.89 DYRK1A (0.40) PDE10ACCR1NCF1HTR1ADYRK1A
SCHEMBL23343768 0.84 PDE10A (0.45) PDE10ANCF1ACACBHTR1AHDAC1
SCHEMBL14182008 0.81 PDE10A (0.41) PDE10ANCF1ACACBHTR1AHDAC1
SCHEMBL8226692 0.80 CCR1 (0.34) PDE10ACCR1HTR1ANPSR1PGK1
SCHEMBL4065110 0.80 NPSR1 (0.36) PDE10ACCR1NPSR1PGK1PGK2
SCHEMBL17778301 0.79 PDE10A (0.40) PDE10ANCF1ACACBHTR1AHDAC1
SCHEMBL30514180 0.79 PDE10A (0.43) PDE10ANCF1ACACBHTR1AHDAC1
SCHEMBL1844596 0.79 PDE10A (0.43) PDE10ANCF1ACACBHTR1AHDAC1
SCHEMBL13240992 0.79 PDE10A (0.40) PDE10ACCR1NCF1ACACBHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-20250144093-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2025-05-08 — — US disclosed
US-12133853-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-11-05 — — US disclosed
CN-114302886-B Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2024-03-22 — — CN disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
CN-117186119-A Pyruvate kinase activators for the treatment of hematological disorders 安吉奥斯医药品有限公司 2023-12-08 — — CN disclosed
CN-111032046-B Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2023-09-26 — — CN disclosed
CN-111032045-B Pyruvate kinase activators for the treatment of hematological disorders 安吉奥斯医药品有限公司 2023-08-15 — — CN disclosed
US-20200207785-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) 2020-07-02 — — US disclosed
US-20200207785-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) 2020-07-02 — — US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 — — US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 — — US disclosed
EP-3668513-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
EP-3668512-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
CN-111032046-A Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2020-04-17 — — CN disclosed
CN-111032045-A Pyruvate kinase activators for the treatment of blood disorders 安吉奥斯医药品有限公司 2020-04-17 — — CN disclosed
WO-2019035865-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC. (US) 2019-02-21 — — WO disclosed
WO-2019035864-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872225-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 PDE10A 1042/4885CCR1 4245/4885NCF1 3835/4885
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 PDE10A 1042/4885CCR1 4245/4885NCF1 3835/4885
US-12133853-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 PDE10A 1702/4885CCR1 2572/4885NCF1 2741/4885
US-20200207785-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 PDE10A 1749/4885CCR1 2625/4885NCF1 2530/4885
US-20250144093-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 PDE10A 1702/4885CCR1 2572/4885NCF1 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.